HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Kimio Yonesaka(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Hiroki Goto(Utsunomiya University), Hidetoshi Hayashi(Kindai University), Masanori Funabashi(Daiichi Sankyo (Germany)), Hiroaki Okida(Daiichi Sankyo (Germany)), Maki Kobayashi(Daiichi-Sankyo (Japan)), Osamu Maenishi(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Eri Otsuka(Daiichi Sankyo (Germany)), Takashi Kagari(Daiichi Sankyo (Germany)), Junko Tanizaki(Kindai University Sakai Hospital), Kenji Hirotani(Daiichi Sankyo (Germany)), Yuuri Hashimoto(Daiichi-Sankyo (Japan)), Kaoru Tanaka(Kindai University), Asuka Tsuya(Izumi City General Hospital), Kazuto Nishio(Kindai University Sakai Hospital), Ryoto Yoshimoto(Daiichi Sankyo (Germany)), Hisato Kawakami(Tohoku University)
Cited by 92
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k